Australian study finds lower doses of rituximab may be effective in treating NMOSD
28 August 2024
A new Australian study has found that lower doses of rituximab may be an effective and safe treatment for NMOSD.
A new Australian study has found that lower doses of rituximab may be an effective and safe treatment for NMOSD.
Researchers develop new molecule to boost myelin repair in MS.
In November 2024, the Pharmaceutical Benefits Advisory Committee (PBAC) will meet to consider a proposal to recommend adding ravulizumab (Ultomiris®) to the Pharmaceutical Benefits Scheme (PBS) for adults with NMOSD.
Jen Willis, the first Australian with multiple sclerosis to attempt to summit Mount Everest, recently led a trek to Everest Base Camp with ten others, including six others living with MS.
MS Australia CEO Rohan Greenland reflects on Chair Des Graham’s tenure in the wake of his retirement announcement and his extraordinary contribution to the MS community.
Associate Professor Des Graham has brought forward his previously announced intention to retire at the end of 2025, and will now conclude his term as Chair at the MS Australia Board Meeting and Annual General Meeting to be held in Sydney on 28 November 2024.
New MS Australia research funding announced today aims to unlock new insights into disease progression, address social needs for better MS care, and identify biological signs of MS. 
Three MS researchers have been awarded incubator grants, which aim to explore new ideas in MS research, giving them the opportunity to test their innovative ideas. 
In 2024, Emeritus Professor Michael Pender was made a Member of the Order of Australia for significant service to medicine, particularly neurology and MS research, and to tertiary education.